Genetically predicted serum urate and cancer risk: a Mendelian randomization study
Authors' conclusion
Our MR study found no consistent evidence of a causal effect of genetically predicted SU on overall or Q3 common site-specific cancers in European individuals.
Study context
- Population
- Individuals of European ancestry: Malmö Diet and Cancer Study (MDCS) and Malmö Preventive Project (MPP) (southern Sweden), Global Urate Genetic Consortium (GUGC) and UK Biobank summary statistics
- Comparison
- Genetically predicted serum urate levels and risk of overall and site-specific cancers
- Outcome
- Risk of 13 site-specific cancers and 'any cancer'
Methodological detailsone-sample Mendelian randomization (MR) (MDCS-MPP), two-sample MR (GUGC and UK Biobank), 26 serum urate (SU)-related variants as instrumental variables, epidemiological association analyses on individual-level data
- One-sample MR (MDCS-MPP)
- Two-sample MR (GUGC and UK Biobank)
- 26 SU-related variants as instrumental variables
- Epidemiological association analyses on individual-level data
Main finding
As reported in the abstract
- Higher genetically predicted SU and lower risk of brain cancer (suggestive; one-sample MR)
- p = 0.04
- Higher genetically predicted SU and lower risk of colorectal cancer (suggestive; two-sample MR)
- p = 0.02
- No significant associations between SU levels and risk of other cancers
- all p > 0.05
Original publication
Genetically predicted serum urate and cancer risk: a Mendelian randomization study. Scand J Rheumatol. Published 30 June 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →